Ypsomed Holding Beheer

Beheer criteriumcontroles 4/4

De CEO Ypsomed Holding is Simon Michel, benoemd in Jul2014, heeft een ambtstermijn van 10.33 jaar. De totale jaarlijkse vergoeding van { bedraagt CHF 1.04M, bestaande uit 62.2% salaris en 37.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.3% van de aandelen van het bedrijf, ter waarde CHF 67.45M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.6 jaar en 4.3 jaar.

Belangrijke informatie

Simon Michel

Algemeen directeur

CHF 1.0m

Totale compensatie

Percentage CEO-salaris	62.2%
Dienstverband CEO	10.3yrs
Eigendom CEO	1.3%
Management gemiddelde ambtstermijn	7.6yrs
Gemiddelde ambtstermijn bestuur	4.3yrs

Recente managementupdates

Here's Why Ypsomed Holding AG's (VTX:YPSN) CEO May Deserve A Raise

Jun 19

Recent updates

Investors Appear Satisfied With Ypsomed Holding AG's (VTX:YPSN) Prospects

Aug 13

There Are Reasons To Feel Uneasy About Ypsomed Holding's (VTX:YPSN) Returns On Capital

Jul 31

If EPS Growth Is Important To You, Ypsomed Holding (VTX:YPSN) Presents An Opportunity

Jul 03

Here's Why Ypsomed Holding AG's (VTX:YPSN) CEO May Deserve A Raise

Jun 19

Should You Investigate Ypsomed Holding AG (VTX:YPSN) At CHF395?

Jun 10

Here's What Analysts Are Forecasting For Ypsomed Holding AG (VTX:YPSN) After Its Full-Year Results

May 25

Investors Appear Satisfied With Ypsomed Holding AG's (VTX:YPSN) Prospects

May 08

Investors Could Be Concerned With Ypsomed Holding's (VTX:YPSN) Returns On Capital

Apr 07

Is There Now An Opportunity In Ypsomed Holding AG (VTX:YPSN)?

Mar 09

Here's Why We Think Ypsomed Holding (VTX:YPSN) Might Deserve Your Attention Today

Feb 07

These 4 Measures Indicate That Ypsomed Holding (VTX:YPSN) Is Using Debt Reasonably Well

Jan 17

Is Now The Time To Put Ypsomed Holding (VTX:YPSN) On Your Watchlist?

Dec 27

Investors Shouldn't Be Too Comfortable With Ypsomed Holding's (VTX:YPSN) Robust Earnings

Nov 24

What Is Ypsomed Holding AG's (VTX:YPSN) Share Price Doing?

Oct 19

Why Ypsomed Holding AG (VTX:YPSN) Could Be Worth Watching

Jul 14

Here's What's Concerning About Ypsomed Holding's (VTX:YPSN) Returns On Capital

Jun 20

Should You Investigate Ypsomed Holding AG (VTX:YPSN) At CHF161?

Feb 28

Analyse CEO-vergoeding

Hoe is Simon Michel's beloning veranderd ten opzichte van Ypsomed Holding's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2024	CHF 1m	CHF 650k	CHF 78m
Dec 31 2023	n/a	n/a	CHF 75m
Sep 30 2023	n/a	n/a	CHF 72m
Jun 30 2023	n/a	n/a	CHF 62m
Mar 31 2023	CHF 1m	CHF 650k	CHF 51m
Dec 31 2022	n/a	n/a	CHF 41m
Sep 30 2022	n/a	n/a	CHF 31m
Jun 30 2022	n/a	n/a	CHF 27m
Mar 31 2022	CHF 1m	CHF 640k	CHF 23m
Sep 30 2021	n/a	n/a	CHF 6m
Jun 30 2021	n/a	n/a	CHF 6m
Mar 31 2021	CHF 851k	CHF 587k	CHF 6m
Sep 30 2020	n/a	n/a	CHF 11m
Jun 30 2020	n/a	n/a	CHF 11m
Mar 31 2020	CHF 668k	CHF 540k	CHF 12m
Dec 31 2019	n/a	n/a	CHF 12m
Sep 30 2019	n/a	n/a	CHF 12m
Jun 30 2019	n/a	n/a	CHF 36m
Mar 31 2019	CHF 851k	CHF 521k	CHF 60m
Dec 31 2018	n/a	n/a	CHF 72m
Sep 30 2018	n/a	n/a	CHF 85m
Jun 30 2018	n/a	n/a	CHF 68m
Mar 31 2018	CHF 783k	CHF 442k	CHF 52m

Compensatie versus markt: De totale vergoeding ($USD 1.17M ) Simon } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Swiss markt ($USD 1.98M ).

Compensatie versus inkomsten: De vergoeding van Simon is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Simon Michel (47 yo)

10.3yrs

Tenure

CHF 1,044,600

Compensatie

Mr. Simon Michel has been Member of the Board of Ypsomed Holding AG since June 29, 2022 and serves as its Chief Executive Officer since July 2014. Mr. Michel served as a Senior Vice President of Marketing...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Simon Michel	CEO & Member of the Board	10.3yrs	CHF 1.04m	1.3% CHF 67.4m
Samuel Kunzli	Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Frank Mengis	Chief Operating Officer	9.1yrs	geen gegevens	0.0055% CHF 284.8k
Thomas Kutt	Head of Investor Relations	no data	geen gegevens	geen gegevens
Nicolas Meyer	Chief Legal Officer & Secretary	1.5yrs	geen gegevens	geen gegevens
Michael Zaugg	Chief Corporate Officer	7.6yrs	geen gegevens	0.00019% CHF 9.9k
Ulrike Bauer	Chief Business Officer of Ypsomed Delivery Systems	23.8yrs	geen gegevens	0.0051% CHF 266.1k
Sebastien Delarive	Chief Business Officer of Ypsomed Diabetes Care	2.4yrs	geen gegevens	0.0050% CHF 261.4k

7.6yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van YPSN is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Simon Michel	CEO & Member of the Board	2.4yrs	CHF 1.04m	1.3% CHF 67.4m
Gilbert Achermann	Independent Chairman	4.3yrs	CHF 196.20k	0.077% CHF 4.0m
Martin Münchbach	Independent Director	5.4yrs	CHF 118.20k	0.0029% CHF 152.0k
Paul Fonteyne	Independent Vice Chairman	6.4yrs	CHF 117.50k	geen gegevens
Betul Unaran	Independent Non-Executive Director	3.4yrs	CHF 118.20k	geen gegevens

4.3yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van YPSN wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

Ypsomed Holding Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Here's Why Ypsomed Holding AG's (VTX:YPSN) CEO May Deserve A Raise

Ypsomed Holding AG, Annual General Meeting, Jun 26, 2024

Ypsomed Holding AG, Annual General Meeting, Jun 28, 2023

No independent directors

No independent directors

Recent updates

New minor risk - Share price stability

Ypsomed Group and CamDiab Receives Health Canada Approval for mylife YpsoPump and CamAPS FX and Provide an Enhancing Diabetes Management

Now 23% undervalued

Now 21% undervalued

Ypsomed Holding AG to Report First Half, 2025 Results on Nov 13, 2024

Investors Appear Satisfied With Ypsomed Holding AG's (VTX:YPSN) Prospects

MTD Medical Technology and Devices S.A. completed the acquisition of the Pen Needle and Blood Glucose Monitoring Businesses of Ypsomed Holding AG (SWX:YPSN).

MTD Medical Technology and Devices S.A. completed the acquisition of the Pen Needle and Blood Glucose Monitoring Businesses of Ypsomed Holding AG (SWX:YPSN).

There Are Reasons To Feel Uneasy About Ypsomed Holding's (VTX:YPSN) Returns On Capital

If EPS Growth Is Important To You, Ypsomed Holding (VTX:YPSN) Presents An Opportunity

Price target increased by 7.6% to CHF378

Here's Why Ypsomed Holding AG's (VTX:YPSN) CEO May Deserve A Raise

Should You Investigate Ypsomed Holding AG (VTX:YPSN) At CHF395?

Here's What Analysts Are Forecasting For Ypsomed Holding AG (VTX:YPSN) After Its Full-Year Results

Full year 2024 earnings released: EPS: CHF5.74 (vs CHF3.82 in FY 2023)

Investor sentiment improves as stock rises 17%

Ypsomed Holding AG to Report Q4, 2024 Results on May 22, 2024

Investors Appear Satisfied With Ypsomed Holding AG's (VTX:YPSN) Prospects

Price target increased by 14% to CHF365

Investors Could Be Concerned With Ypsomed Holding's (VTX:YPSN) Returns On Capital

Is There Now An Opportunity In Ypsomed Holding AG (VTX:YPSN)?

Here's Why We Think Ypsomed Holding (VTX:YPSN) Might Deserve Your Attention Today

We Think Ypsomed Holding (VTX:YPSN) Can Stay On Top Of Its Debt

Ypsomed Holding AG's (VTX:YPSN) Popularity With Investors Is Clear

Here's What's Concerning About Ypsomed Holding's (VTX:YPSN) Returns On Capital

Should You Investigate Ypsomed Holding AG (VTX:YPSN) At CHF298?

First half 2024 earnings released: EPS: CHF2.68 (vs CHF1.17 in 1H 2023)

Do Ypsomed Holding's (VTX:YPSN) Earnings Warrant Your Attention?

Price target increased by 14% to CHF315

Ypsomed Holding AG to Report First Half, 2024 Results on Nov 15, 2023

Ypsomed Holding (VTX:YPSN) Seems To Use Debt Quite Sensibly

Ypsomed Holding (VTX:YPSN) May Have Issues Allocating Its Capital

Should You Think About Buying Ypsomed Holding AG (VTX:YPSN) Now?

Ypsomed Holding AG, Annual General Meeting, Jun 26, 2024

Upcoming dividend of €1.30 per share at 0.5% yield

Should You Be Adding Ypsomed Holding (VTX:YPSN) To Your Watchlist Today?

Consensus EPS estimates increase by 15%

Ypsomed Holding (VTX:YPSN) Seems To Use Debt Quite Sensibly

Price target increased by 13% to CHF257

Ypsomed Holding AG to Report Fiscal Year 2023 Results on May 24, 2023

What Does Ypsomed Holding AG's (VTX:YPSN) Share Price Indicate?

Ypsomed Holding (VTX:YPSN) Could Be Struggling To Allocate Capital

Ypsomed Holding AG, Annual General Meeting, Jun 28, 2023

At CHF187, Is It Time To Put Ypsomed Holding AG (VTX:YPSN) On Your Watch List?

These 4 Measures Indicate That Ypsomed Holding (VTX:YPSN) Is Using Debt Reasonably Well

Price target increased to CHF223

Mediq B.V. completed the acquisition of DiaExpert GmbH from Ypsomed Holding AG (SWX:YPSN).

Is Now The Time To Put Ypsomed Holding (VTX:YPSN) On Your Watchlist?

Investor sentiment deteriorated over the past week

Now 21% undervalued

Investors Shouldn't Be Too Comfortable With Ypsomed Holding's (VTX:YPSN) Robust Earnings

Consensus forecasts updated

Price target increased to CHF207

First half 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

No independent directors

What Is Ypsomed Holding AG's (VTX:YPSN) Share Price Doing?

Price target decreased to CHF192

Why Ypsomed Holding AG (VTX:YPSN) Could Be Worth Watching

Upcoming dividend of CHF0.60 per share

Here's What's Concerning About Ypsomed Holding's (VTX:YPSN) Returns On Capital

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Ypsomed Holding AG to Report Fiscal Year 2022 Results on May 25, 2022

Price target increased to CHF218

No independent directors

Now 20% undervalued after recent price drop

Should You Investigate Ypsomed Holding AG (VTX:YPSN) At CHF161?

Now 21% undervalued

Consensus EPS estimates increase by 32%

Now 20% undervalued

Price target increased to CHF178